Assessing the Value of Avocados on Glycemic Control in Type 2 Diabetes

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorPennington Biomedical Research Center

About this trial

The objective of this study is to assess the effects of Hass Avocados on glycemic control. The investigators hypothesize that Hass Avocado consumption will reduce fasting blood sugar compared to an isocaloric amount of other fruit during controlled feeding.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Participant reported diagnosis of Type 2 diabetes

HbA1c between 5.7%-11% (inclusive) and / or fasting blood glucose of ≥ 100 mg/dL

BMI 27-50 kg/m2 (inclusive)

Age range - 18 - 65 years (inclusive)

Disqualifiers

Not willing or unable to consume study foods including avocados

Participation in a weight control program within the past 3 months or weight loss of ≥ 5 kg in the previous 3 months

Taking prescription or OTC weight loss medications within last 4 weeks

History of a surgical procedure for weight loss in last 5 years (e.g. gastroplasty, gastric by-pass, gastrectomy or partial gastrectomy, adjustable banding, gastric sleeve)

Trial design

Design model

Crossover

Treatments tested in this trial

  • Avocado

    Other intervention

    The Hass Avocado group will consume 7 avocados a week (1 / day; \~240 kcals/d).

  • Other Fruit(s)

    Other intervention

    The other fruits group will consume fruit(s) matched to the avocado in energy and form (i.e., solid fruit).

Treatment groups

48 Participants
are divided into 2 treatment groups
Group A: AvocadoExperimental treatment 1 intervention
Group B: Other Fruit(s)Active comparator 1 intervention

Trial outcomes

Primary outcomes

1

Fasting Blood Glucose

the primary outcomes are based on within subject concentration change scores

Time frame
Week 5 - Week 0

Secondary outcomes

1

Fasting Insulin

within subject concentration change scores

Time frame
Week 5 - Week 0
2

Fructosamine

within subject concentration change scores

Time frame
Week 5 - Week 0
3

Glycated Albumin

within subject concentration change scores

Time frame
Week 5 - Week 0

Other outcomes

1

Blood Glucose

Continuous Glucose Monitoring

Time frame
Week 5 - Week 0
2

Glucose

Oral Glucose Tolerance Test (OGTT)

Time frame
Week 5 - Week 0
3

Insulin

Oral Glucose Tolerance Test (OGTT)

Time frame
Week 5 - Week 0

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Pennington Biomedical Research Center

Lead sponsor

Prachi Singh

Collaborator

Frank L. Greenway

Collaborator

Robbie A. Beyl

Collaborator